Medical Xpress reported on Thursday that schizophrenia and type 2 diabetes are linked, and that GLP-1 drugs could play a role in managing the risks tied to both conditions.
According to Medical Xpress, the connection between the two conditions is established, and GLP-1 medications — the class of drugs used for weight loss and diabetes — may help address the risks that come with it.
Coverage of the same research points to a specific finding. Quartz reported that weight loss drugs are linked to fewer psychiatric admissions among people who have both schizophrenia and diabetes. The Irish Sun, in its own report, described the same class of drugs as potentially able to halt depression and schizophrenia symptoms.
The reports surfaced together on Thursday, drawing attention to how a treatment originally developed for metabolic disease might affect psychiatric outcomes in patients dealing with both diagnoses.
The available reporting does not include the size of the study, the patient population, or the specific figures behind the admission numbers, so the scale of the effect is not yet clear from these accounts.
What to watch next: whether the researchers behind the finding publish full results, and whether further studies confirm that GLP-1 drugs can reduce psychiatric hospitalizations in this patient group.
